Developer docs
API playgroundTry for free, no card

Search company profiles

Biocartis

Full company profile

uuid0002eaq

Namestring
Biocartis
Legal namestring
Biocartis NV
Websiteurl
biocartis.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Biocartis NV is a Belgium-headquartered molecular diagnostics company that develops and commercializes the Idylla Platform, a fully automated, real-time PCR-based sample-to-answer system designed to deliver oncology biomarker results in approximately 3 hours with less than 3 minutes of hands-on time. The company serves clinical laboratories, oncologists, pathologists, oncology researchers, and pharmaceutical partners, with a menu spanning FDA-approved and IVDR-certified companion diagnostic tests (including the Idylla CDx MSI Test for colorectal cancer), IVD oncology assays (EGFR, BRAF, KRAS, NRAS-BRAF, MSI, GeneFusion Panel), an extensive RUO research assay portfolio, and APIS-branded dPCR/qPCR kits. It reaches approximately 2,000 customers across 75+ countries through a hybrid model combining direct enterprise field sales, Molecular Technical Specialist-led demonstrations, and an extensive global distributor network, with a wholly-owned US subsidiary (Biocartis US Inc.) supporting North American operations. Revenue is generated through Idylla instrument hardware sales plus recurring cartridge consumables, RUO assay sales, and pharmaceutical CDx partnership and licensing arrangements. Biocartis operates with approximately 200 employees, has cumulatively raised roughly $418M across nine disclosed funding rounds between 2009 and 2020, and has undergone a major corporate restructuring while continuing to extend its regulatory footprint (FDA approval and EU IVDR Class C certification) and platform menu.

Short descriptiontext

Biocartis is a Belgium-based molecular diagnostics company that commercializes the Idylla Platform — a fully automated real-time PCR system delivering oncology biomarker results in approximately 3 hours — serving clinical laboratories, oncologists, pathologists, and pharmaceutical CDx partners across 75+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMechelen, Belgium
HQ citystring
Mechelen
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular diagnostics, companion diagnostics, PCR testing systems, oncology biomarker assays, clinical diagnostic instruments
Industry5 codes
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code4 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Services-Testing Laboratories8734
Product category
Molecular Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Idylla Platform Hardware
TypeHardware Sales
Description

Sale of Idylla instrument systems to laboratories and healthcare institutions. The platform is a benchtop molecular diagnostics system that labs purchase to run Biocartis cartridge-based tests.

biocartis.com
2Diagnostic Test Cartridges (Consumables)
TypeOne Time License
Description

Recurring revenue from sale of proprietary test cartridges for use on the Idylla platform. Tests include EGFR, BRAF, KRAS, NRAS-BRAF, MSI, GeneFusion Panel, and other oncology biomarker assays.

biocartis.com
3Research Assays (RUO)
TypeOne Time License
Description

Sale of Research Use Only assays for biomarker investigation, including POLE-POLD1, IDH1-2, PIK3CA-AKT1, ctEGFR, ctKRAS, and ctNRAS-BRAF mutation assays.

biocartis.com
4Pharmaceutical Partnership & Licensing
TypeLicensing Royalties
Description

Partnerships with pharmaceutical companies for companion diagnostic development and co-commercialization, including licensing of patents and technology.

biocartis.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Idylla
Description

Fully automated molecular testing platform for oncology diagnostics providing sample-to-answer results in approximately 3 hours

biocartis.com
+2 more records
Core offering1 text field

Biocartis develops and commercializes the Idylla Platform, a fully automated real-time PCR-based molecular testing system that delivers sample-to-answer oncology biomarker results in approximately 3 hours with less than 3 minutes of hands-on time. The company sells the benchtop Idylla instrument together with proprietary single-use test cartridges (IVD and RUO) covering cancer biomarkers such as EGFR, BRAF, KRAS, NRAS, MSI, gene fusions, ctDNA targets, and additional research markers. It also partners with pharmaceutical companies to co-develop companion diagnostics and licenses related technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 97% concordance with standard MSI/dMMR testing methods
+2 more records
Product overview1 text field

Biocartis is a molecular diagnostics company offering the Idylla Platform, a fully automated, sample-to-answer real-time PCR system for oncology diagnostics. The product portfolio consists of the Idylla Platform as the core instrument system, complemented by FDA-approved and IVDR-certified companion diagnostic tests (including Idylla CDx MSI Test for colorectal cancer) and a comprehensive menu of IVD oncology tests (EGFR, BRAF, KRAS, NRAS-BRAF, MSI, GeneFusion Panel). The company also provides an extensive range of Research Use Only (RUO) assays covering the same biomarkers plus additional targets (POLE-POLD1, IDH1-2, PIK3CA-AKT1, ThyroidPrint) and liquid biopsy assays (ctEGFR, ctKRAS, ctNRAS-BRAF-EGFR S492R). Additionally, Biocartis offers APIS branded digital PCR (dPCR) and quantitative PCR (qPCR) kits for research applications. The platform delivers results in approximately 3 hours with minimal hands-on time, enabling rapid molecular testing suitable for any laboratory setting.

Product and service20 records
1Idylla Platform
CategoryDiagnostic instrument platform
Description

A fully automated, real-time PCR based benchtop molecular testing system that provides sample-to-answer diagnostics. Delivers molecular biomarker results in approximately 3 hours with less than 3 minutes hands-on time, designed to make molecular testing easy, fast and suitable for any laboratory setting without specialized molecular expertise.

2Idylla CDx MSI Test
CategoryCompanion diagnostic (IVD) test cartridge
Description

FDA-approved and IVDR Class C certified companion diagnostic test for rapid detection of microsatellite instability-high (MSI-H) in colorectal cancer tissue samples. Indicated as an aid to identify adult patients with MSI-H metastatic colorectal cancer who may benefit from treatment with nivolumab in combination with ipilimumab.

3Idylla EGFR Mutation Test
CategoryIVD diagnostic test cartridge
Description

Real-time PCR IVD test for detection of EGFR mutations, used in oncology diagnostics for lung cancer and other applications on the Idylla Platform.

4Idylla BRAF Mutation Test
CategoryIVD diagnostic test cartridge
Description

Real-time PCR IVD test for detection of BRAF mutations, used in melanoma and colorectal cancer diagnostics on the Idylla Platform.

5Idylla KRAS Mutation Test
CategoryIVD diagnostic test cartridge
Description

Real-time PCR IVD test for detection of KRAS mutations, used in colorectal cancer and other oncology applications on the Idylla Platform.

6Idylla NRAS-BRAF Mutation Test
CategoryIVD diagnostic test cartridge
Description

Real-time PCR IVD test for simultaneous detection of NRAS and BRAF mutations on the Idylla Platform.

7Idylla MSI Test
CategoryIVD diagnostic test cartridge
Description

Real-time PCR IVD test for microsatellite instability detection in colorectal cancer tissue samples on the Idylla Platform.

8Idylla GeneFusion Panel
CategoryIVD diagnostic test cartridge
Description

Real-time PCR panel for detection of gene fusions used in oncology diagnostics on the Idylla Platform.

9Idylla EGFR Mutation Assay (RUO)
CategoryResearch use only (RUO) assay cartridge
Description

Research use only assay for detection of EGFR mutations, providing the same technology as the IVD test for research applications on the Idylla Platform.

10Idylla MSI Assay (RUO)
CategoryResearch use only (RUO) assay cartridge
Description

Research use only assay that performs detection of microsatellite instability from FFPE tissue. Detects mutations in 7 MSI loci (ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A, and SULF2) with approximately 150 minutes turnaround time and less than 3 minutes hands-on time. Does not require paired normal tissue samples.

11Idylla POLE-POLD1 Mutation Assay (RUO)
CategoryResearch use only (RUO) assay cartridge
Description

Research use only assay for detection of POLE and POLD1 mutations on the Idylla Platform.

12Idylla ThyroidPrint Assay (RUO)
CategoryResearch use only (RUO) assay cartridge
Description

Research use only assay for thyroid cancer diagnostics on the Idylla Platform.

13Idylla IDH1-2 Mutation Assay (RUO)
CategoryResearch use only (RUO) assay cartridge
Description

Research use only assay kit for detection of IDH1 and IDH2 mutations on the Idylla Platform.

14Idylla PIK3CA-AKT1 Mutation Assay (RUO)
CategoryResearch use only (RUO) assay cartridge
Description

Research use only assay for detection of PIK3CA and AKT1 mutations on the Idylla Platform.

15Idylla ctEGFR Mutation Assay (RUO)
CategoryResearch use only (RUO) assay cartridge (liquid biopsy)
Description

Circulating tumor DNA assay for research use only, detecting EGFR mutations from liquid biopsy samples on the Idylla Platform.

16Idylla ctKRAS Mutation Assay (RUO)
CategoryResearch use only (RUO) assay cartridge (liquid biopsy)
Description

Circulating tumor DNA assay for research use only, detecting KRAS mutations from liquid biopsy samples on the Idylla Platform.

17Idylla ctNRAS-BRAF-EGFR S492R Mutation Assay (RUO)
CategoryResearch use only (RUO) assay cartridge (liquid biopsy)
Description

Circulating tumor DNA assay for research use only, detecting NRAS, BRAF, and EGFR S492R mutations from liquid biopsy samples on the Idylla Platform.

18APIS ESR1 dPCR Kit (RUO)
CategoryResearch use only (RUO) PCR kit
Description

Digital PCR kit for research use only, detecting ESR1 mutations. Distributed under the APIS brand as part of Biocartis' research assay portfolio.

19APIS ESR1 qPCR Kit (RUO)
CategoryResearch use only (RUO) PCR kit
Description

Quantitative PCR kit for research use only, detecting ESR1 mutations. Distributed under the APIS brand as part of Biocartis' research assay portfolio.

20APIS ESR1 & PIK3CA qPCR Kits Bundle (RUO)
CategoryResearch use only (RUO) PCR kit bundle
Description

Bundle of quantitative PCR kits for research use only, detecting both ESR1 and PIK3CA mutations. Distributed under the APIS brand as part of Biocartis' research assay portfolio.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-09
Description

Biocartis announced an agreement with City of Hope to explore development of a rapid, blood-based, sample-to-answer gene signature test for early detection of pancreatic cancer on the Idylla Platform. Under the deal, Biocartis secured an option to license key patents and related know-how from City of Hope to accelerate test development. The test remains investigational and not yet available for diagnostic use. Dr. Ajay Goel of City of Hope noted that their microRNA-based liquid biopsy signature platform has demonstrated ability to detect cancers that current FDA-approved noninvasive tests miss across multiple international patient cohorts.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biocartis

Molecular Diagnosticsbiocartis.com

Biocartis is a Belgium-based molecular diagnostics company that commercializes the Idylla Platform — a fully automated real-time PCR system delivering oncology biomarker results in approximately 3 hours — serving clinical laboratories, oncologists, pathologists, and pharmaceutical CDx partners across 75+ countries.

What Biocartis does

Biocartis NV is a Belgium-headquartered molecular diagnostics company that develops and commercializes the Idylla Platform, a fully automated, real-time PCR-based sample-to-answer system designed to deliver oncology biomarker results in approximately 3 hours with less than 3 minutes of hands-on time. The company serves clinical laboratories, oncologists, pathologists, oncology researchers, and pharmaceutical partners, with a menu spanning FDA-approved and IVDR-certified companion diagnostic tests (including the Idylla CDx MSI Test for colorectal cancer), IVD oncology assays (EGFR, BRAF, KRAS, NRAS-BRAF, MSI, GeneFusion Panel), an extensive RUO research assay portfolio, and APIS-branded dPCR/qPCR kits. It reaches approximately 2,000 customers across 75+ countries through a hybrid model combining direct enterprise field sales, Molecular Technical Specialist-led demonstrations, and an extensive global distributor network, with a wholly-owned US subsidiary (Biocartis US Inc.) supporting North American operations. Revenue is generated through Idylla instrument hardware sales plus recurring cartridge consumables, RUO assay sales, and pharmaceutical CDx partnership and licensing arrangements. Biocartis operates with approximately 200 employees, has cumulatively raised roughly $418M across nine disclosed funding rounds between 2009 and 2020, and has undergone a major corporate restructuring while continuing to extend its regulatory footprint (FDA approval and EU IVDR Class C certification) and platform menu.

Biocartis firmographics

Firmographics
Name
Biocartis
Legal name
Biocartis NV
Website
https://biocartis.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
Biocartis is a Belgium-based molecular diagnostics company that commercializes the Idylla Platform — a fully automated real-time PCR system delivering oncology biomarker results in approximately 3 hours — serving clinical laboratories, oncologists, pathologists, and pharmaceutical CDx partners across 75+ countries.
Ownership category
akta.pro rank

Biocartis industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Molecular diagnostics
  • Companion diagnostics
  • PCR testing systems
  • Oncology biomarker assays
  • Clinical diagnostic instruments

Where Biocartis is headquartered

Location

Headquarters

HQ city
Mechelen
HQ country
Belgium
HQ region
Europe

Offices2 records

Markets served

Biocartis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Idylla Platform Hardware: Sale of Idylla instrument systems to laboratories and healthcare institutions. The platform is a benchtop molecular diagnostics system that labs purchase to run Biocartis cartridge-based tests.
  2. Diagnostic Test Cartridges (Consumables): Recurring revenue from sale of proprietary test cartridges for use on the Idylla platform. Tests include EGFR, BRAF, KRAS, NRAS-BRAF, MSI, GeneFusion Panel, and other oncology biomarker assays.
  3. Research Assays (RUO): Sale of Research Use Only assays for biomarker investigation, including POLE-POLD1, IDH1-2, PIK3CA-AKT1, ctEGFR, ctKRAS, and ctNRAS-BRAF mutation assays.
  4. Pharmaceutical Partnership & Licensing: Partnerships with pharmaceutical companies for companion diagnostic development and co-commercialization, including licensing of patents and technology.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Biocartis product offering

Product offering

Core offering

Biocartis develops and commercializes the Idylla Platform, a fully automated real-time PCR-based molecular testing system that delivers sample-to-answer oncology biomarker results in approximately 3 hours with less than 3 minutes of hands-on time. The company sells the benchtop Idylla instrument together with proprietary single-use test cartridges (IVD and RUO) covering cancer biomarkers such as EGFR, BRAF, KRAS, NRAS, MSI, gene fusions, ctDNA targets, and additional research markers. It also partners with pharmaceutical companies to co-develop companion diagnostics and licenses related technology.

Product overview

Biocartis is a molecular diagnostics company offering the Idylla Platform, a fully automated, sample-to-answer real-time PCR system for oncology diagnostics. The product portfolio consists of the Idylla Platform as the core instrument system, complemented by FDA-approved and IVDR-certified companion diagnostic tests (including Idylla CDx MSI Test for colorectal cancer) and a comprehensive menu of IVD oncology tests (EGFR, BRAF, KRAS, NRAS-BRAF, MSI, GeneFusion Panel). The company also provides an extensive range of Research Use Only (RUO) assays covering the same biomarkers plus additional targets (POLE-POLD1, IDH1-2, PIK3CA-AKT1, ThyroidPrint) and liquid biopsy assays (ctEGFR, ctKRAS, ctNRAS-BRAF-EGFR S492R). Additionally, Biocartis offers APIS branded digital PCR (dPCR) and quantitative PCR (qPCR) kits for research applications. The platform delivers results in approximately 3 hours with minimal hands-on time, enabling rapid molecular testing suitable for any laboratory setting.

Differentiator

Problem solved

Functional benefit

Brands

  • Idylla: Fully automated molecular testing platform for oncology diagnostics providing sample-to-answer results in approximately 3 hours
  • Idylla CDx MSI Test
  • Idylla MSI Test

Products and services

  • Idylla Platform A fully automated, real-time PCR based benchtop molecular testing system that provides sample-to-answer diagnostics. Delivers molecular biomarker results in approximately 3 hours with less than 3 minutes hands-on time, designed to make molecular testing easy, fast and suitable for any laboratory setting without specialized molecular expertise.
  • Idylla CDx MSI Test FDA-approved and IVDR Class C certified companion diagnostic test for rapid detection of microsatellite instability-high (MSI-H) in colorectal cancer tissue samples. Indicated as an aid to identify adult patients with MSI-H metastatic colorectal cancer who may benefit from treatment with nivolumab in combination with ipilimumab.
  • Idylla EGFR Mutation Test Real-time PCR IVD test for detection of EGFR mutations, used in oncology diagnostics for lung cancer and other applications on the Idylla Platform.
  • Idylla BRAF Mutation Test Real-time PCR IVD test for detection of BRAF mutations, used in melanoma and colorectal cancer diagnostics on the Idylla Platform.
  • Idylla KRAS Mutation Test Real-time PCR IVD test for detection of KRAS mutations, used in colorectal cancer and other oncology applications on the Idylla Platform.
  • Idylla NRAS-BRAF Mutation Test Real-time PCR IVD test for simultaneous detection of NRAS and BRAF mutations on the Idylla Platform.
  • Idylla MSI Test Real-time PCR IVD test for microsatellite instability detection in colorectal cancer tissue samples on the Idylla Platform.
  • Idylla GeneFusion Panel Real-time PCR panel for detection of gene fusions used in oncology diagnostics on the Idylla Platform.
  • Idylla EGFR Mutation Assay (RUO) Research use only assay for detection of EGFR mutations, providing the same technology as the IVD test for research applications on the Idylla Platform.
  • Idylla MSI Assay (RUO) Research use only assay that performs detection of microsatellite instability from FFPE tissue. Detects mutations in 7 MSI loci (ACVR2A, BTBD7, DIDO1, MRE11, RYR3, SEC31A, and SULF2) with approximately 150 minutes turnaround time and less than 3 minutes hands-on time. Does not require paired normal tissue samples.
  • Idylla POLE-POLD1 Mutation Assay (RUO) Research use only assay for detection of POLE and POLD1 mutations on the Idylla Platform.
  • Idylla ThyroidPrint Assay (RUO) Research use only assay for thyroid cancer diagnostics on the Idylla Platform.
  • Idylla IDH1-2 Mutation Assay (RUO) Research use only assay kit for detection of IDH1 and IDH2 mutations on the Idylla Platform.
  • Idylla PIK3CA-AKT1 Mutation Assay (RUO) Research use only assay for detection of PIK3CA and AKT1 mutations on the Idylla Platform.
  • Idylla ctEGFR Mutation Assay (RUO) Circulating tumor DNA assay for research use only, detecting EGFR mutations from liquid biopsy samples on the Idylla Platform.
  • Idylla ctKRAS Mutation Assay (RUO) Circulating tumor DNA assay for research use only, detecting KRAS mutations from liquid biopsy samples on the Idylla Platform.
  • Idylla ctNRAS-BRAF-EGFR S492R Mutation Assay (RUO) Circulating tumor DNA assay for research use only, detecting NRAS, BRAF, and EGFR S492R mutations from liquid biopsy samples on the Idylla Platform.
  • APIS ESR1 dPCR Kit (RUO) Digital PCR kit for research use only, detecting ESR1 mutations. Distributed under the APIS brand as part of Biocartis' research assay portfolio.
  • APIS ESR1 qPCR Kit (RUO) Quantitative PCR kit for research use only, detecting ESR1 mutations. Distributed under the APIS brand as part of Biocartis' research assay portfolio.
  • APIS ESR1 & PIK3CA qPCR Kits Bundle (RUO) Bundle of quantitative PCR kits for research use only, detecting both ESR1 and PIK3CA mutations. Distributed under the APIS brand as part of Biocartis' research assay portfolio.

Quantifiable outcome

  • Over 97% concordance with standard MSI/dMMR testing methods
  • +2 more outcomes

Companies that use Biocartis

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Biocartis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Biocartis partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • City of HopecoreStrategic or Co-development Partner · 9 June 2026Biocartis announced an agreement with City of Hope to explore development of a rapid, blood-based, sample-to-answer gene signature test for early detection of pancreatic cancer on the Idylla Platform. Under the deal, Biocartis secured an option to license key patents and related know-how from City of Hope to accelerate test development. The test remains investigational and not yet available for diagnostic use. Dr. Ajay Goel of City of Hope noted that their microRNA-based liquid biopsy signature platform has demonstrated ability to detect cancers that current FDA-approved noninvasive tests miss across multiple international patient cohorts.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Biocartis competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights6 records

Customer concentration

Biocartis social profiles

Digital presence

Biocartis compliance and trust

Trust signal

Compliance2 records

Biocartis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biocartis leadership team

Management profile

Number of profiles

Profiles18 records

Biocartis subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Biocartis funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biocartis M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biocartis

What does Biocartis do?

Biocartis develops and commercializes the Idylla Platform, a fully automated real-time PCR-based molecular testing system that delivers sample-to-answer oncology biomarker results in approximately 3 hours with less than 3 minutes of hands-on time. The company sells the benchtop Idylla instrument together with proprietary single-use test cartridges (IVD and RUO) covering cancer biomarkers such as EGFR, BRAF, KRAS, NRAS, MSI, gene fusions, ctDNA targets, and additional research markers. It also partners with pharmaceutical companies to co-develop companion diagnostics and licenses related technology.

Is Biocartis a public or private company?

Biocartis is a private company. It is classified as venture growth investor backed and is currently operating.

When was Biocartis founded?

Biocartis was founded in 2007. It employs 101 to 250 people.

Where is Biocartis based?

Biocartis is headquartered in Mechelen, Belgium, in the Europe region.

How does Biocartis make money?

Four revenue lines are on record. Idylla Platform Hardware is the primary driver. The others are diagnostic Test Cartridges (Consumables), research Assays (RUO) and pharmaceutical Partnership & Licensing.

Does Biocartis have an API?

No public API is recorded for Biocartis.

What industry is Biocartis in?

Biocartis's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD), with a secondary code of HLAAAMAA, Biomarker Discovery & Validation (omics, assay feasibility, clinical validation). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Clinical Lab ProductsBiocartis Earns European Certification for Colorectal Cancer Companion Diagnostic TestBiocartis has received Class C companion diagnostic certification under the EU's In Vitro Diagnostic Medical Device Regulation for its Idylla CDx MSI Test. This approval enables the identification of patients with metastatic colorectal cancer who may benefit from treatment with nivolumab and ipilimumab, expanding the company's IVDR-approved portfolio. The test, which delivers results in under three hours, is now set to become available to customers across Europe and other regions applying IVDR regulations.GlobeNewswirePress Release Biocartis NV: Biocartis Showcases Growing Impact of Idylla™ Platform at AMP 2025Biocartis announced the adoption and validation of its Idylla™ platform in multiple research and clinical settings during the AMP 2025 meeting in Boston. The platform demonstrated high accuracy, fast turnaround, and utility in diagnosing various cancer mutations, supporting personalized treatment strategies.GlobeNewswireEurope Molecular Oncology Diagnostics Market Research Report 2024-2033 | Competitive Analysis of Biocartis Group, bioMerieux, F. Hoffmann-La Roche, QIAGENThe Europe molecular oncology diagnostics market is projected to grow from $606M in 2024 to $1.52B by 2033, a 10.78% CAGR. Growth is driven by next-generation sequencing, digital PCR, and liquid biopsy, with Western Europe leading adoption. Challenges include cost, reimbursement, and regulatory issues.GlobeNewswireEurope Molecular Oncology Diagnostics Market Research Report 2024-2033 | Competitive Analysis of Biocartis Group, bioMerieux, F. Hoffmann-La Roche, QIAGENThe Europe molecular oncology diagnostics market was valued at $606 million in 2024 and is projected to reach $1.52 billion by 2033, growing at a 10.78% CAGR. Growth is driven by next-generation sequencing, digital PCR, and liquid biopsy, with Western Europe leading adoption. Challenges include high costs and inconsistent reimbursement.GlobeNewswirePress release Biocartis Group NV: Biocartis Group NV provides an update regarding the publication of its annual report and the annual meetingBiocartis Group NV postponed publication of its 2023 Annual Report and the convening notice for its AGM, which was initially set for 10 May 2024. The delay is due to preparation for a voluntary dissolution and liquidation to be submitted to an extraordinary general shareholders' meeting. The company will announce the publication and convening at a later date.GlobeNewswirePress release Biocartis Group NV: Disclosure ofInvesco Ltd. disclosed a downward crossing of the 3% voting rights threshold in Biocartis Group NV on January 3, 2024, after transferring all its shares. The notification, amended on January 8, 2024, shows Invesco no longer holds any voting rights, having previously held 9,240,331 shares.GlobeNewswirePress release Biocartis Group NV: Disclosure ofJPMorgan Chase & Co. acquired shares in Biocartis Group NV on January 3, 2024, exceeding the 5% participation threshold. The notification, dated January 5, 2024, shows the company now holds 5.16% of voting rights, with 4,842,106 voting rights and 4,942,745 including similar financial instruments.GlobeNewswirePress release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansionBiocartis completed its recapitalization, converting €132 million of debt into equity and adding €40 million in new investment. The company launched three breast cancer products, including the Idylla PIK3CA-AKT1 assay and APIS kits, with thyroid and melanoma assays planned for Q4 2023.GlobeNewswirePress release Biocartis Group NV: Announcement regarding Enforcement by Secured CreditorsBiocartis Group NV's secured creditors enforced their security over the company's subsidiaries, transferring shares and cash to a new unlisted holding company. The enforcement reduced debt by EUR 132 million, and the new company will inject at least EUR 40 million in equity. Biocartis Group NV is expected to be wound down and delisted.GlobeNewswirePress release Biocartis Group NV: Four Abstracts ShowingBiocartis announced four study abstracts on its Idylla assays were selected for poster presentations at ESMO in Madrid. The studies show the GeneFusion and EGFR Mutation Assays offer rapid, sensitive, and specific lung sample profiling, with over 5,000 cases tested and a 15% EGFR mutation frequency in early-stage NSCLC.